First Trust Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-28,731
| Closed | -$559K | – | 2519 |
|
|
2023
Q2 | $559K | Buy |
28,731
+359
| +1% | +$6.98K | ﹤0.01% | 2111 |
|
|
2023
Q1 | $805K | Buy |
28,372
+2,113
| +8% | +$59.9K | ﹤0.01% | 2022 |
|
|
2022
Q4 | $768K | Sell |
26,259
-1,891
| -7% | -$55.3K | ﹤0.01% | 2052 |
|
|
2022
Q3 | $744K | Buy |
28,150
+11,393
| +68% | +$301K | ﹤0.01% | 2091 |
|
|
2022
Q2 | $745K | Sell |
16,757
-856
| -5% | -$38.1K | ﹤0.01% | 2081 |
|
|
2022
Q1 | $872K | Sell |
17,613
-1,012
| -5% | -$50.1K | ﹤0.01% | 2091 |
|
|
2021
Q4 | $948K | Buy |
18,625
+2,057
| +12% | +$105K | ﹤0.01% | 2082 |
|
|
2021
Q3 | $924K | Buy |
+16,568
| New | +$924K | ﹤0.01% | 2067 |
|
|
2019
Q1 | – | Sell |
-7,551
| Closed | -$304K | – | 2463 |
|
|
2018
Q4 | $304K | Buy |
+7,551
| New | +$304K | ﹤0.01% | 2261 |
|
|
2017
Q4 | – | Sell |
-21,472
| Closed | -$1.28M | – | 2474 |
|
|
2017
Q3 | $1.28M | Sell |
21,472
-3,741
| -15% | -$223K | ﹤0.01% | 1735 |
|
|
2017
Q2 | $1.99M | Buy |
+25,213
| New | +$1.99M | 0.01% | 1467 |
|